ACET vs. ADMA, URI, FAST, GWW, WSO, WCC, AIT, AL, GATX, and MSM
Should you be buying Adicet Bio stock or one of its competitors? The main competitors of Adicet Bio include ADMA Biologics (ADMA), United Rentals (URI), Fastenal (FAST), W.W. Grainger (GWW), Watsco (WSO), WESCO International (WCC), Applied Industrial Technologies (AIT), Air Lease (AL), GATX (GATX), and MSC Industrial Direct (MSM).
Adicet Bio vs. Its Competitors
ADMA Biologics (NASDAQ:ADMA) and Adicet Bio (NASDAQ:ACET) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.
In the previous week, ADMA Biologics had 3 more articles in the media than Adicet Bio. MarketBeat recorded 5 mentions for ADMA Biologics and 2 mentions for Adicet Bio. Adicet Bio's average media sentiment score of 0.83 beat ADMA Biologics' score of 0.60 indicating that Adicet Bio is being referred to more favorably in the news media.
75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by company insiders. Comparatively, 7.8% of Adicet Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ADMA Biologics currently has a consensus target price of $27.67, suggesting a potential upside of 77.24%. Adicet Bio has a consensus target price of $5.33, suggesting a potential upside of 534.92%. Given Adicet Bio's higher probable upside, analysts plainly believe Adicet Bio is more favorable than ADMA Biologics.
ADMA Biologics has a net margin of 44.06% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 41.01% beat Adicet Bio's return on equity.
ADMA Biologics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
Summary
ADMA Biologics beats Adicet Bio on 10 of the 15 factors compared between the two stocks.
Get Adicet Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACET and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adicet Bio Competitors List
Related Companies and Tools
This page (NASDAQ:ACET) was last updated on 9/28/2025 by MarketBeat.com Staff
Free ACET Stock Alerts